Kraig Biocraft Laboratories Announces Commencement of Full Operations at Second Production Rearing Center in Southeast Asia
Rhea-AI Summary
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has announced the full operational status of its second production rearing center in Southeast Asia. This expansion creates parallel operations with their existing facility, enabling continuous rearing cycles of specialized recombinant spider silk silkworms.
The new facility is working with BAM-1 production hybrids and three additional parental lines introduced in summer 2025. The dual-site strategy aims to eliminate previous production bottlenecks while increasing resilience and scalability. The expansion supports the company's commercialization strategy and strengthens their spider silk production platform.
Positive
- Establishment of second fully operational production facility enhances production capacity and reliability
- Integration of three new genetic lines expands breeding program capabilities
- Dual-site strategy eliminates previous production bottlenecks
- Enhanced operational redundancy improves production consistency and scalability
Negative
- Previous production bottlenecks have affected operations in the past
News Market Reaction
On the day this news was published, KBLB gained 0.63%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Parallel facilities strengthen continuous production and accelerate spider silk advancements
ANN ARBOR, Mich., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that its second production rearing center in Southeast Asia is now fully operational.
With two active production facilities, Kraig Labs has established parallel operations designed to ensure continuous rearing cycles of its specialized recombinant spider silk silkworms. This dual-site capacity increases resilience and scalability, providing greater material output consistency, as Kraig Labs advances its commercialization strategy.
Teams are now active at both rearing centers, working with the Company's established parental lines for BAM-1 production hybrids, as well as three additional parental lines introduced earlier this summer. These new genetic lines represent a significant expansion of the Company’s breeding program and are expected to further enhance production efficiencies.
These facilities are designed to create efficient redundancy to avoid bottlenecks the Company experienced in the past. This is a major leap forward in terms of creating sustained production.
"Becoming fully operational at our second rearing center is a milestone that strengthens the foundation of our spider silk production platform," said Kim Thompson, founder and CEO of Kraig Labs. "Having parallel operations allows us to maintain continuous rearing cycles, diversify our breeding program, and accelerate the development of next-generation hybrids. This expanded capacity is essential as we push forward in scaling production and bringing our recombinant spider silk to market."
The opening of this second rearing facility reflects the Company’s ongoing commitment to building a robust, reliable, and scalable spider silk production system in Southeast Asia, positioning Kraig Labs to meet growing demand from diverse markets and industries.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc. (720) 288-8495 ir@KraigLabs.com
FAQ
What is the significance of KBLB's second production facility in Southeast Asia?
How many production facilities does Kraig Biocraft Laboratories now operate in Southeast Asia?
What genetic lines is KBLB currently working with in its production facilities?
How will the new facility impact KBLB's commercialization strategy?
What challenges has KBLB faced in production previously?
